胸腺肽α1对高龄肿瘤患者淋巴细胞免疫功能的影响

Clinical observation of Thymosin α1 on the influence of immune function of lymphocyte in elderly tumor patients

目的探讨胸腺肽α1对高龄肿瘤患者T细胞、B细胞、NK细胞的影响。方法将40例肿瘤患者分为两组,每组各20例。实验组除常规治疗外,皮下注射胸腺肽α1注射液1.6 mg,每日1次,连续14~21 d;对照组仅进行常规治疗。采用流式细胞仪检测两组患者治疗前后外周血T细胞CD3＋、CD4＋、CD8＋和NK细胞阳性百分率及CD4＋/CD8＋比值,并观察血白细胞、血红蛋白、血小板变化,肝功能改变、严重感染发生情况、患者生活状态改变等临床疗效相关指标。结果实验组用药后CD3＋、CD4＋、和NK的阳性百分率及CD4＋/CD8＋比值,均高于实验组用药前和对照组用药后水平（P〈0.05）;而临床疗效指标两组间未见明显差异（P〉0.05）。结论胸腺肽α1对高龄肿瘤患者淋巴细胞免疫功能有显著影响。

Objective To in the investigate the influence of Thymosin α1 on T cells, B cells, and NK cells in elderly tumor patients, and to observe its clinical therapeutic effects. Methods Totally 40 tumor patients were divided into 2 groups（with 20 patients in each group）. For the experimental group, other than conventional therapy, the patients were administrated with hypodermic injections for 1.6 mg of Thymosin al injection once a day, for a continuous of 14 to 21 days. While, for the control group, only conventional therapy was performed. For both groups, flow eytometry was carried out to test positive percentage of T cells CD3 ＋ , CD4 ＋, CD8 ＋ and NK cells, as well as the ratio of CD4 ＋/CD8＋ in peripheral blood before and after treatment, and changes in white blood cells, hemoglobin, and blood platelet,change in liver function, severe infection occurrence, change in patients＇ state of living and other clinical therapeutic effect related indices were observed. Results Both of the positive percentage of T cells CD3＋ , CD4＋ , CD8＋ , NK cells, and the ratio of CD4＋/CDs＋ of the experimental group after treatment were higher than those before treatment, and higher than those of the control group （ P 〈 0.05 ） ; while, there are no obvious differences in clinical therapeutic effect related indices between the two groups （ P 〉 0.05 ）. Conclusion Thymosin α1 has a notable influence on the immune function of lymphocyte in elderly tumor patients.